Transcriptomics

Dataset Information

0

Gene expression profiling of neuroendocrine primary tumors: effect of Octreotide treatment


ABSTRACT: The management of neuroendocrine tumors (NETs) is very variable, depending on many specific aspects, such as the type of tumor, spread and patient general health. Several advances have been made with the newly developed somatostatin analogues to cure this type of malignancies. Somatostain analogues such as octreotide have been used in clinic to treat patients with neuroendocrine tumors (NETs). However, the molecular mechanism leading either to successful therapy or acquired resistance to the analogues is still to large extent unclear. Patients develop drugs resistance during a long term treatment. Therefore, to identify the pivotal regulatory genes involved in the development of drug resistance is an actual challenge. We studied five human neuroendocrine tumor cell lines, CNDT2.5, KRJ1, QGP-1, NCI H720 and NCI H727. We also investigated a long-term treated CNDT2.5 by using octreotide. We performed gene expression profiling in all the human neuroendocrine cell lines. Keywords: Gene Expression profiling, treatment comparison

ORGANISM(S): Homo sapiens

PROVIDER: GSE24358 | GEO | 2012/12/12

SECONDARY ACCESSION(S): PRJNA132815

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2012-12-12 | E-GEOD-24358 | biostudies-arrayexpress
2013-01-08 | E-MTAB-388 | biostudies-arrayexpress
| 2145354 | ecrin-mdr-crc
| 2365307 | ecrin-mdr-crc
2012-11-08 | E-MTAB-862 | biostudies-arrayexpress
2022-05-20 | PXD029979 | Pride
2017-12-31 | GSE80021 | GEO
2016-12-31 | GSE65286 | GEO
| 2743256 | ecrin-mdr-crc
2013-03-01 | GSE33568 | GEO